Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02314364 · ClinicalTrials.gov registry record · Phase 2
A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT02314364: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT02314364 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02314364, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
This research study is studying a type of radiation therapy called Stereotactic Body Radiation Therapy (SBRT) as a possible treatment for stage IV non-small cell lung cancer (NSCLC) that has a mutated epidermal growth factor receptor (EGFR) or or displaced anaplastic lymphoma receptor tyrosine kinase (ALK) or ROS proto-oncogene 1 (ROS1) gene (= oncogene-driven NSCLC) and for which the subject has been receiving treatment with a targeted biological agent such as erlotinib, crizotinib, or other drugs.
Interventions
- RADIATION SBRT with protons or photons
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2014-12 |
| Est. Completion | 2023-10-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02314364
The ClinicalTrials.gov registry entry for NCT02314364 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SBRT with protons or photons is the first listed.
NCT02314364 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02314364 about?
NCT02314364 is a clinical study titled "A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC". This research study is studying a type of radiation therapy called Stereotactic Body Radiation Therapy (SBRT) as a possible treatment for stage IV non-small cell lung cancer (NSCLC) that has a mutated epidermal growth factor receptor (EGFR) or or displaced anaplastic lymphoma receptor tyrosine kinas...
What is the current status of trial NCT02314364?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2014-12. Estimated completion is 2023-10-25.
What interventions are being tested in trial NCT02314364?
The interventions under investigation include: SBRT with protons or photons (RADIATION).
Who is sponsoring clinical trial NCT02314364?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.